Patel AP. Potential for Bridging Treatment Gaps in Cardiovascular Health in Asia With Inclusive Clinical Trials. JACC. Asia. 2024;4(2):135-137. doi:10.1016/j.jacasi.2023.11.008.
Fahed AC, Natarajan P. Clinical applications of polygenic risk score for coronary artery disease through the life course. Atherosclerosis. 2023;386:117356. doi:10.1016/j.atherosclerosis.2023.117356.
Hasbani NR, Westerman KE, Kwak SH, et al. Type 2 Diabetes Modifies the Association of CAD Genomic Risk Variants With Subclinical Atherosclerosis. Circulation. Genomic and precision medicine. 2023;16(6):e004176. doi:10.1161/CIRCGEN.123.004176.
Figtree GA, Vernon ST, Harmer JA, et al. Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2023;82(13):1343-1359. doi:10.1016/j.jacc.2023.06.045.
DeForest N, Kavitha B, Hu S, et al. Human gain-of-function variants in HNF1A confer protection from diabetes but independently increase hepatic secretion of atherogenic lipoproteins. Cell genomics. 2023;3(7):100339. doi:10.1016/j.xgen.2023.100339.
Chiu Y-W, Su M-H, Lin Y-F, Chen C-Y, Chen T-T, Wang S-H. Causal influence of sleeping phenotypes on the risk of coronary artery disease and sudden cardiac arrest: A Mendelian randomization analysis. Sleep health. 2023. doi:10.1016/j.sleh.2023.05.009.
Cho SMJ, Koyama S, Honigberg MC, et al. Genetic, sociodemographic, lifestyle, and clinical risk factors of recurrent coronary artery disease events: a population-based cohort study. European heart journal. 2023. doi:10.1093/eurheartj/ehad380.
Natarajan P. Polygenic Risk Scoring for Coronary Heart Disease: The First Risk Factor. J Am Coll Cardiol. 2018;72(16):1894-1897. doi:10.1016/j.jacc.2018.08.1041.
Gupta RM. Hippo Pathway Looms Large for the Function of the JCAD (Junctional Protein Associated With Coronary Artery Disease) on Endothelial Cells. Arterioscler Thromb Vasc Biol. 2018;38(11):2546-2547. doi:10.1161/ATVBAHA.118.311342.